1. Home
  2. BUD vs VRTX Comparison

BUD vs VRTX Comparison

Compare BUD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

BUD

Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

SELL

Current Price

$83.48

Market Cap

162.0B

ML Signal

SELL

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

SELL

Current Price

$534.26

Market Cap

135.6B

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
BUD
VRTX
Founded
1366
1989
Country
Belgium
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
EDP Services
Sector
Consumer Staples
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
162.0B
135.6B
IPO Year
2016
2006

Fundamental Metrics

Financial Performance
Metric
BUD
VRTX
Price
$83.48
$534.26
Analyst Decision
Buy
Buy
Analyst Count
12
32
Target Price
$94.89
★ $595.36
AVG Volume (30 Days)
★ 2.4M
1.4M
Earning Date
10-29-2026
11-02-2026
Dividend Yield
★ 1.92%
N/A
EPS Growth
N/A
★ 836.54
EPS
N/A
★ 10.90
Revenue
N/A
★ $2,488,652,000.00
Revenue This Year
$9.31
$10.46
Revenue Next Year
$3.45
$10.53
P/E Ratio
★ $23.27
$49.34
Revenue Growth
N/A
★ 46.20
52 Week Low
$59.90
$412.27
52 Week High
$86.60
$568.67

Technical Indicators

Market Signals
Indicator
BUD
VRTX
Relative Strength Index (RSI) 53.59 49.75
Support Level $77.90 $493.75
Resistance Level $85.70 $536.58
Average True Range (ATR) 1.30 16.14
MACD -0.09 -1.47
Stochastic Oscillator 68.93 14.27

Price Performance

Historical Comparison
BUD
VRTX

About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)

Anheuser-Busch InBev is the largest brewer in the world and one of the top five consumer product companies by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 acquired SABMiller.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Share on Social Networks: